GNTA
Genenta ScienceGNTA
GNTA
$4.19
2.56%
Market Cap: 76.3M
About: Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
Employees: 14
0
Funds holding %
of 6,702 funds
–
Analysts bullish %
–
News positive %
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 4 [Q4 2023] → 4 (+0) [Q1 2024]
2.03% less ownership
Funds ownership: 4.64% [Q4 2023] → 2.61% (-2.03%) [Q1 2024]
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
53% less capital invested
Capital invested by funds: $3.67M [Q4 2023] → $1.74M (-$1.93M) [Q1 2024]
Research analyst outlook
1 Wall Street Analyst provided 1 year price forecasts over the past 6 months
Low target
$25
497%
upside
Avg. target
$25
497%
upside
High target
$25
497%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis | 497%upside $25 | Buy Reiterated | 13 May 2024 |